About the API
General Information
Midostaurin is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutationpositive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
At Teva api, we offer two forms of midostaurin for development purposes — amorphous and Form II. Our deep expertise in the development and production of fermentation products, as well as 50+ years of experience in strain improvement performed in a dedicated site, really set us apart.